Assay for analysis of free drug in samples

• US 8,389,224 B2
• Filed: 04/18/2011
• Issued: 03/05/2013
• Est. Priority Date: 05/24/2004
• Status: Expired due to Fees

• Current Assignee: Laboratory Corporation Of America Holdings
• Original Assignee: Laboratory Corporation Of America Holdings
• Inventors: Purvis, Norman B., Stelzer, Gregory T.
• Primary Examiner(s): Gabel, Gail R
• Application Number:
  US13/088,841
• Publication Number:
  US 20110212469A1
• Time in Patent Office: 687 Days
• Field of Search: 435/6, 435/7.1, 435/7.2, 435/7.24, 435/40.51, 435/287.2, 436/501, 436/517, 436/522, 436/537, 436/538, 436/10, 436/17, 436/18, 436/63, 436/164, 436/172, 436175-177, 422/73, 422/82.08, 530/388.2, 424/9.2
• US Class Current: 435/7.2
• CPC Class Codes: G01N 2333/70514 CD4
• CPC Class Codes: G01N 2333/70553 Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
• CPC Class Codes: G01N 2333/70596 Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
• CPC Class Codes: G01N 2333/7158 for chemokines
• CPC Class Codes: G01N 33/5008 for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
• CPC Class Codes: G01N 33/5091 for testing the pathological state of an organism
• CPC Class Codes: G01N 33/6854 Immunoglobulins
• CPC Class Codes: G01N 33/6863 Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
• CPC Class Codes: G01N 33/6872 Intracellular protein regulatory factors and their receptors, e.g. including ion channels
• CPC Class Codes: G01N 33/94 involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
• CPC Class Codes: Y10T 436/101666 Particle count or volume standard or control [e.g., platelet count standards, etc.]

Abstract

Whole cell, simultaneous target and drug-target assay using differentially labeled antibodies and flow cytometry. First antibody binds to total target and second antibody binds to the drug binding site of the target, thus drug binding will competitively inhibit the second antibody allowing for a competitive inhibition assay of drug-target binding. The assay allows for whole cell analysis and even analysis of mixed populations of cells, yet provides detailed kinetic assessment of drug activity.

Claims

1. A method of measuring free drug present in a biological sample from a subject, comprising:

(a) combining a biological sample from a subject who is taking the drug with a target cell, wherein the biological sample comprises a biological fluid sample, and wherein the target cell expresses a target that interacts with the drug to bind to at least a portion of the drug present in the biological fluid sample,

(b) mixing the target cell of step (a) that has been combined with the free drug present in the biological sample with a labeled anti-Free-Site antibody, wherein the anti-Free Site antibody is a monoclonal antibody that recognizes and binds to an epitope on the target when the drug is not bound to the target but is competitively inhibited by binding of the drug to the target;

(c) washing away unbound anti-Free-Site antibody from the target cell of step (b);

(d) fixing the target cell of step (c);

(e) quantifying the amount of anti-Free-Site antibody binding to the target cell of step (d) by flow cytometry; and

(f) determining the amount of free drug present in the biological sample by comparing the amount of anti-Free-Site antibody bound to the target cell as quantified in step (e) to a standard curve of pre-determined amounts of Anti-Free-Site antibody bound to target cells previously exposed to known amounts of the drug, wherein the standard curve illustrates a correlation between the amount of Anti-Free Site antibody bound to target cells and the amount of drug reacted with the target cells, and correlating the amount of anti-Free-Site antibody bound to the target cell to the amount of free drug present in the biological sample based on the standard curve.

2. The method of claim 1, further comprising reacting the target cell of step (a) with a labeled anti-Total antibody and quantifying the amount of anti-Total antibody bound to the target cell to determine the total amount of target expressed by the target cell wherein the anti-Total antibody comprises a monoclonal antibody that binds to an epitope on the target that is different from both the epitope bound by the anti-Free-Site antibody and the epitope bound by the drug.

3. The method of claim 2, wherein the anti-Total antibody is conjugated to a dye or fluorescent label that is different than the dye or fluorescent label conjugated to the anti-Free Site antibody.

4. The method of claim 3, wherein the anti-Free-Site antibody and the anti-Total antibody are each conjugated to a different dye or fluorescent label.

5. The method of claim 2, wherein the anti-Total Antibody comprises an anti-human CD11 a antibody, an anti-human CD11b antibody, an anti-human CD18 antibody, an anti-human CD22 antibody, an anti-human CD25 antibody, an anti-human CD20 antibody, an anti-human CD52 antibody, an anti-human CD33 antibody, an anti-human CD4 antibody, an anti-human CD3 antibody, an anti-human CD14 antibody, an anti-human CD30 antibody, an anti-human HLA antibody, an anti-human MAP kinase antibody, an anti-human RAF-1 antibody, an anti-human AKT antibody, an anti-human BCL-2 antibody, an anti-human chemokine receptor antibody, or an anti-human ESRA antibody.

6. The method of claim 1, wherein the target cell of step (a) and the target cells of step (f) are permeabilized target cells.

7. The method of claim 6, wherein the target cell of step (a) is permeabilized prior to step (b).

8. The method claim 1, wherein the anti-Free Site antibody is conjugated to a dye or fluorescent label.

9. The method of claim 1, wherein the anti-Free-Site Antibody comprises an anti-human CD11a antibody, an anti-human CD11b antibody, an anti-human CD18 antibody, an anti-human CD22 antibody, an anti-human CD25 antibody, an anti-human CD20 antibody, an anti-human CD52 antibody, an anti-human CD33 antibody, an anti-human CD4 antibody, an anti-human CD3 antibody, an anti-human CD14 antibody, an anti-human CD30 antibody, an anti-human HLA antibody, an anti-human MAP kinase antibody, an anti-human RAF-1 antibody, an anti-human AKT antibody, an anti-human BCL-2 antibody, an anti-human chemokine receptor antibody, or an anti-human ESRA antibody.

10. The method of claim 1, wherein the standard curve of step (f) is generated by the method comprising:

(i) exposing separate aliquots of target cells to known amounts of the drug, wherein the target cells are the same type of target cell combined with the biological sample from the subject;

(ii) combining the aliquots of the target cells of (i) with the labeled Anti-Free-Site antibody;

(iii) washing away the unbound anti-Free-Site antibody from the aliquots of the target cells of (ii);

(iv) fixing the aliquots of the target cells of step (iii);

(v) quantifying the amount of Anti-Free-Site antibody binding to the aliquots of the target cells of step (iv); and

(vi) preparing the standard curve showing the relationship between the drug concentration and the quantified binding of the anti-Free-Site antibody to the aliquots of target cells of step (v).

11. The method of claim 10, wherein the aliquots of target cells of (i) are exposed to a permeabilization agent prior to step (ii).

12. The method of claim 1, wherein the biological sample comprises blood, plasma, serum, or bone marrow.

13. The method of claim 1, wherein step (e) is performed by flow cytometry.

14. The method of claim 1, wherein the target cell comprises a cell line that constitutively expresses the target to which the drug binds.